A Phase 2/3 interventional study of Sarilumab and Placebo in COVID-19, sponsored by Regeneron Pharmaceuticals. Completed at 62 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-23.
Sponsored by Regeneron Pharmaceuticals · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in COVID-19 by Regeneron Pharmaceuticals — none open to participants now, none under way, none of them phase 3. COVID-19 · Regeneron Pharmaceuticals.
Among the 13 studies in COVID-19 by Regeneron Pharmaceuticals, this one is the 3rd largest by enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2020, is the only one in phase 2/3, and was the 1st registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →None of the 13 studies in COVID-19 by Regeneron Pharmaceuticals is open now. The open studies under COVID-19, anywhere →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 5 · Phase 3 3
First in 2020; this study’s year is marked. 5 started in 2020.
This study's enrollment of 1,912 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 57 across the 12 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in COVID-19 by Regeneron Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Phase 2:
The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 regardless of disease severity strata.
Phase 3 Cohort 1:
The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with critical COVID-19 receiving mechanical ventilation at baseline.
Phase 3 Cohort 2:
The primary objective of the study is to evaluate the clinical efficacy of sarilumab relative to the control arm in adult patients hospitalized with COVID-19 receiving mechanical ventilation at baseline.
Phase 2 and Phase 3 Cohort 1 completed. Cohorts 2 and 3 terminated early based on Phase 3 Cohort 1 results.
Key Inclusion Criteria:
Meets 1 of the following criteria at baseline:
Patients must be receiving mechanical ventilation to treat respiratory failure due to COVID-19
Patients must be receiving supplemental oxygen to treat hypoxemia delivered by one of the following devices:
Key Exclusion Criteria:
NOTE: Other protocol defined inclusion / exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 2
Drug: Sarilumab · Drug: Placebo
Phase 3: Cohort 1
Drug: Sarilumab · Drug: Placebo
Phase 2
Drug: Sarilumab · Drug: Placebo
Phase 3: Cohort 1
Drug: Sarilumab · Drug: Placebo
Phase 3: Cohort 2
Drug: Sarilumab · Drug: Placebo
Phase 3: Cohort 3
Drug: Sarilumab · Drug: Placebo
Single or multiple intravenous (IV) doses of sarilumab. Additional doses may be administered if the patient meets protocol defined criteria.
Also known as: Kevzara®, REGN88, SAR153191
Single or multiple intravenous (IV) doses of placebo to match sarilumab administration
Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2)
Percent Change from Baseline in C-Reactive Protein (CRP) Levels at Day 4 in Participants with Serum Interleukin 6 (IL-6) Level Greater than the Upper Limit of Normal (ULN) Least Squares (LS) means estimate of percent change from baseline at Day 4 (raw scale) for each treatment group is based on the Analysis of Covariance (ANCOVA) model. It is defined as anti-log of the estimate of dependent variable minus 1, i.e., (exp\[ln(CRP at day 4/Baseline CRP)\]-1. Negative numbers imply improvement in CRP.
Time frame: Baseline and Day 4
Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1)
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Day 22
Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2)
The ordinal scale is an assessment of the clinical status of a participant The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Day 22
Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2)
Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with serum IL-6 levels greater than the upper limit of normal (ULN). The ordinal scale is an assessment of the clinical status of a patient. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Up to Day 29
Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2)
Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with all serum IL-6 levels. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Up to Day 29
Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2)
Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner, in patients with documented fever ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary) at Baseline. Resolution of fever is defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary).
Time frame: Up to Day 29
Time to Resolution of Fever for at Least 48 Hours Without Antipyretics by Clinical Severity (Phase 2)
Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge. Resolution of fever is defined only in participants with presence of fever at baseline.
Time frame: Up to day 29
Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, by Baseline IL-6 Levels (Phase 2)
Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, by baseline IL-6 levels. Resolution of fever is defined only in participants with presence of fever at baseline.
Time frame: Up to Day 29
Time to Improvement in Oxygenation for at Least 48 Hours (Phase 2)
Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2
Time frame: Up to day 29
Time to Improvement in Oxygenation for at Least 48 Hours by Baseline IL-6 Levels (Phase 2)
Time to Improvement defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2
Time frame: Up to day 29
Time to Resolution of Fever and Improvement in Oxygenation for at Least 48 Hours (Phase 2)
Resolution of fever defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary) Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2
Time frame: Up to day 29
Percentage of Participants in Each Clinical Status Category Using the 7-point Ordinal Scale up to Day 29 (Phase 2)
Percentage of participants in each clinical status category using the 7-point ordinal scale from Baseline (Day 1) up to Day 29. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Days 1, 3, 5, 8, 11, 15 and 29
Time to Discharge or to a National Early Warning Score 2 (NEWS2) of ≤2 and Maintained for 24 Hours (Phase 2)
NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).
Time frame: Up to day 29
Change From Baseline in NEWS2 Scoring System (Phase 2)
NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).
Time frame: Days 3, 5, 8, 11, 15 and 29
Number of Days With Fever (Phase 2)
Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)
Time frame: Up to Day 29
Percentage of Participants Alive, Off Oxygen (Phase 2)
Time frame: At Day 29
Number of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2)
Time frame: Up to day 29
Number of Days With Hypoxemia (Phase 2)
Time frame: Up to day 29
Number of Days of Supplemental Oxygen Use (Phase 2)
Time frame: Up to day 29
Time to Saturation ≥94% on Room Air (Phase 2)
Time frame: Up to day 29
Number of Ventilator Free Days (Phase 2)
Summary of Ventilator-free days during study in Participants using Invasive Mechanical Ventilation at Baseline
Time frame: Up to Day 22
Number of Participants Who Initiated Mechanical Ventilation After Baseline (Phase 2)
Time frame: Up to Day 29
Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2)
Time frame: Up to Day 29
Number of Days of Hospitalization Among Survivors (Phase 2)
Time frame: Up to day 29
Number of Deaths Due to Any Cause
Number of deaths due to any cause (All-Cause Mortality)
Time frame: Up to day 60
Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT)
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Day 22
Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22
Time frame: Day 22
Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT)
Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22
Time frame: Day 22
Percentage of Participants Who Die (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of Participants who die through Day 29 and Day 60
Time frame: Up to Day 29 and Day 60
Percentage of Participants Who Die (Phase 3 Cohort 1: Critical ITT)
Percentage of Participants who die through Day 29 and Day 60
Time frame: Up to Day 29 and Day 60
Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)
Time frame: At Day 22
Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: At Day 22
Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)
Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)
Time frame: At Day 22
Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)
Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: At Day 22
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Up to day 29
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Up to day 29
Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2)
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Up to day 29
Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1)
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Up to day 29
Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT)
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
Time frame: Up to day 29
Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Time frame: Day 22
Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT)
Time frame: Day 22
Percentage of Patients Discharged and Alive (Phase 3 Cohort 1)
Percentage of Patients Discharged and Alive at Day 22
Time frame: At Day 22
Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT)
Percentage of Participants Discharged and Alive at Day 22
Time frame: At Day 22
Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)
Time frame: Up to day 29
Time to Recovery (Phase 3 Cohort 1: Critical ITT)
Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)
Time frame: Up to day 29
Time to Recovery (Phase 3 Cohort 2)
Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)
Time frame: Up to day 29
Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Phase 3 Cohort 1 Time to Death (All-Cause Mortality)
Time frame: Up to day 60
Time to Death (Phase 3 Cohort 1: Critical ITT)
Time to Death (All-Cause Mortality)
Time frame: Up to day 60
Time to Death (Phase 3 Cohort 2)
Time to Death (All-Cause Mortality)
Time frame: Up to day 60
Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline)
Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)
Time frame: Days 8, 15, 22 and 29
Number of Ventilator-Free Days (Phase 3 Cohort 1: Critical ITT)
Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)
Time frame: Days 8, 15, 22 and 29
Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1)
Number of days of hospitalization among survivors (Phase 3 Cohort 1)
Time frame: Days 8, 15, 22 and 29
Number of Days of Hospitalization Among Survivors (Phase 3 Cohort 1: Critical ITT)
Number of days of hospitalization among survivors (Phase 3 Cohort 1: Critical ITT population)
Time frame: Days 8, 15, 22 and 29
Number of Participants With Any Serious Adverse Event
Time frame: Up to day 60
Number of Participants With Grade 4 Neutropenia (ANC <500/mm3)
Grade 4 Neutropenia defined as Absolute Neutrophil Count (ANC) of less than 500 per cubic millimeter(mm3)
Time frame: Up to day 60
Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection
Time frame: Up to day 60
Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection
Time frame: Up to day 60
Number of Participants With Grade >=2 Infusion Related Reactions
Time frame: Up to day 60
Number of Participants With Grade >=2 Hypersensitivity Reactions
Time frame: Up to day 60
Number of Participants With Gastrointestinal Perforation
Time frame: Up to day 60
Mean Observed Leukocyte Values Across Study Days (Phase 2)
Time frame: Days 1, 4, 15 and 29
Mean Observed Leukocyte Values Across Study Days (Phase 3)
Time frame: Days 1, 4, 15 and 29
Mean Observed Hemoglobin Values Across Study Days (Phase 2)
Time frame: Days 1, 4, 15 and 29
Mean Observed Hemoglobin Values Across Study Days (Phase 3)
Time frame: Days 1, 4, 15 and 29
Mean Observed Platelet Count Across Study Days (Phase 2)
Time frame: Days 1, 4, 15 and 29
Mean Observed Platelet Count Across Study Days (Phase 3)
Time frame: Days 1, 4, 15 and 29
Mean Observed Total Bilirubin Values Across Study Days (Phase 2)
Time frame: Days 1, 4, 15 and 29
Mean Observed Total Bilirubin Across Study Days (Phase 3)
Time frame: Days 1, 4, 15 and 29
Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 2)
Time frame: Days 1, 4, 15 and 29
Mean Observed Aspartate Aminotransferase Values Across Study Days (Phase 3)
Time frame: Days 1, 4, 15 and 29
Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 2)
Time frame: Days 1, 4, 15 and 29
Mean Observed Alanine Aminotransferase Values Across Study Days (Phase 3)
Time frame: Days 1, 4, 15 and 29
Mean Observed Creatinine Values Across Study Days (Phase 2)
Time frame: Days 1, 4, 15 and 29
Mean Observed Creatinine Values Across Study Days (Phase 3)
Time frame: Days 1, 4, 15 and 29
| Milestone | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 90 | 187 | 180 | 170 | 242 | 338 | 70 | 140 | 137 | 46 | 95 | 92 | 8 | 12 | 15 | 15 | 16 | 6 | 2 |
| Completed | 61 | 117 | 125 | 101 | 157 | 209 | 52 | 111 | 101 | 29 | 53 | 51 | 5 | 8 | 9 | 9 | 13 | 5 | 2 |
| Not completed | 29 | 70 | 55 | 69 | 85 | 129 | 18 | 29 | 36 | 17 | 42 | 41 | 3 | 4 | 6 | 6 | 3 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 | 2 | 2 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 10 | 6 | 8 | 12 | 13 | 9 | 16 | 14 | 0 | 2 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Death | 24 | 60 | 49 | 59 | 70 | 114 | 9 | 12 | 21 | 16 | 40 | 40 | 3 | 4 | 6 | 4 | 3 | 1 | 0 |
Percent Change from Baseline in C-Reactive Protein (CRP) Levels at Day 4 in Participants with Serum Interleukin 6 (IL-6) Level Greater than the Upper Limit of Normal (ULN) Least Squares (LS) means estimate of percent change from baseline at Day 4 (raw scale) for each treatment group is based on the Analysis of Covariance (ANCOVA) model. It is defined as anti-log of the estimate of dependent variable minus 1, i.e., (exp\[ln(CRP at day 4/Baseline CRP)\]-1. Negative numbers imply improvement in CRP.
| Percent Change | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Percent Change From Baseline in CRP Levels at Day 4 in Participants With Serum IL-6 Level Greater Than the ULN (Phase 2) | -0.20 ± 0.077 | -0.77 ± 0.018 | -0.78 ± 0.017 |
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Percentage of participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants With at Least a 1-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale in Participants With Critical COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 1) | 35.5 (23.6 to 47.4) | 43.3 (33.7 to 52.8) | 43.2 (34.7 to 51.6) |
The ordinal scale is an assessment of the clinical status of a participant The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Percentage of participants | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV |
|---|---|---|
| Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With COVID-19 Receiving Mechanical Ventilation at Baseline (Phase 3 Cohort 2) | 60.0 (35.2 to 84.8) | 68.8 (46.0 to 91.5) |
Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with serum IL-6 levels greater than the upper limit of normal (ULN). The ordinal scale is an assessment of the clinical status of a patient. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With Serum IL-6 Levels Greater Than the Upper Limit of Normal (Phase 2) | 16.0 (11.0 to NA) | 15.0 (12.0 to 21.0) | 14.0 (10.0 to 21.0) |
Time to improvement (2 points) in clinical status assessment on the 7-point ordinal scale in severe or critical participants with all serum IL-6 levels. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Time to Improvement (2 Points) in Clinical Status Assessment in Severe or Critical Patients With All Serum IL-6 Levels (Phase 2) | 15.0 (10.0 to 28.0) | 14.0 (11.0 to 19.0) | 13.0 (10.0 to 18.0) |
Time to resolution of fever for at least 48 hours without antipyretics or until discharge, whichever is sooner, in patients with documented fever ≥38°C (oral), ≥38.4°C (rectal or tympanic), or ≥37.6°C (temporal or axillary) at Baseline. Resolution of fever is defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary).
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Time to Resolution of Fever for at Least 48 Hours Without Antipyretics or Until Discharge, Whichever is Sooner, in Patients With Documented Fever at Baseline (Phase 2) | 17.0 (11.0 to NA) | 18.0 (11.0 to NA) | 18.0 (11.0 to NA) |
Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge. Resolution of fever is defined only in participants with presence of fever at baseline.
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | 7.0 (4.0 to 10.0) | 5.0 (3.0 to 8.0) | 6.0 (5.0 to 11.0) |
| Disease Severity: Critical | NA (15.0 to NA) | 29.0 (16.0 to NA) | 20.5 (11.0 to NA) |
| Disease Severity: Multisystem Organ Dysfunction | NA (11.0 to NA) | NA (17.0 to NA) | NA (18.0 to NA) |
Resolution of fever is defined as body temperature \<=36.8 C (axilla or temporal) or\<= 37.2 C (oral) or \<37.6 C (rectal or tympanic) for at least 48 hours without antipyretics or until discharge, by baseline IL-6 levels. Resolution of fever is defined only in participants with presence of fever at baseline.
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe Baseline IL-6 < 87.04 picograms per milliliter (pg/mL) Median | 8.5 (4.0 to 12.0) | 5.0 (3.0 to 7.0) | 5.0 (3.0 to 6.0) |
| Disease Severity: Severe Baseline IL-6 >= 87.04pg/mL (Median) | 5.0 (3.0 to 8.0) | 8.0 (3.0 to 12.0) | NA (4.0 to NA) |
| Disease Severity: Critical Baseline IL-6 < 166.68pg/mL (Median) | 14.0 (2.0 to NA) | 16.5 (5.0 to NA) | 17.0 (5.0 to NA) |
| Disease Severity: Critical Baseline IL-6 >= 166.68pg/mL (Median) | NA (NA to NA) | NA (16.0 to NA) | 25.0 (12.0 to NA) |
| Disease Severity: MSOD Baseline IL-6 <254.95 pg/mL (Median) | NA (14.0 to NA) | NA (9.0 to NA) | NA (15.0 to NA) |
| Disease Severity: MSOD Baseline IL-6 >= 254.95 pg/mL (Median) | NA (11.0 to NA) | NA (2.0 to NA) | NA (5.0 to NA) |
Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | 7.0 (5.0 to 9.0) | 6.0 (5.0 to 9.0) | 11.0 (6.0 to NA) |
| Disease Severity: Critical | 10.5 (7.0 to NA) | 20.0 (12.0 to NA) | 11.0 (8.0 to 15.0) |
| Disease Severity: MSOD | 20.0 (9.0 to NA) | NA (12.0 to NA) | 19.0 (10.0 to NA) |
Time to Improvement defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Severe Participants Baseline IL-6 < 67.11pg/mL (median) | 8.0 (2.0 to 12.0) | 5.0 (4.0 to 7.0) | 7.5 (4.0 to NA) |
| Severe Participants Baseline IL-6 >= 67.11pg/mL (median) | 6.5 (4.0 to 9.0) | 8.5 (5.0 to 11.0) | NA (11.0 to NA) |
| Critical Participants Baseline IL-6 < 131.90pg/mL (median) | 7.0 (6.0 to NA) | 17.0 (8.0 to NA) | 8.5 (7.0 to 15.0) |
| Critical Participants Baseline IL-6 >= 131.90pg/mL (median) | 15.0 (6.0 to NA) | NA (12.0 to NA) | 14.0 (8.0 to NA) |
| MSOD / Immunocompromised Participants Baseline IL-6 < 254.95pg/mL (median) | 14.0 (3.0 to NA) | NA (7.0 to NA) | 24.0 (7.0 to NA) |
| MSOD / Immunocompromised Participants Baseline IL-6 >= 254.95pg/mL (median) | 24.0 (9.0 to NA) | NA (8.0 to NA) | 19.0 (13.0 to NA) |
Resolution of fever defined as postbaseline body temperature \<37.2°C (oral), or \<37.6°C (rectal or tympanic) or \<36.8°C (temporal or axillary) Improvement in oxygenation defined as increase in SpO2/FiO2 of 50 or greater compared to the nadir SpO2/FiO2
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | 7.0 (4.0 to 7.0) | 4.0 (3.0 to 8.0) | 6.0 (4.0 to NA) |
| Disease Severity: Critical | 15.0 (7.0 to NA) | 22.0 (8.0 to NA) | 8.5 (7.0 to 14.0) |
| Disease Severity: MSOD | 20.0 (8.0 to NA) | NA (9.0 to NA) | 24.0 (9.0 to NA) |
Percentage of participants in each clinical status category using the 7-point ordinal scale from Baseline (Day 1) up to Day 29. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Percentage of Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe Day 1 Ordinal Scale = 1 | 0 | 0 | 0 |
| Disease Severity: Severe Day 1 Ordinal Scale = 2 | 0 | 0 | 7.8 |
| Disease Severity: Severe Day 1 Ordinal Scale = 3 | 0 | 2.0 | 3.9 |
| Disease Severity: Severe Day 1 Ordinal Scale = 4 | 100 | 94.0 | 88.2 |
| Disease Severity: Severe Day 1 Ordinal Scale = 5 | 0 | 4.0 | 0 |
| Disease Severity: Severe Day 1 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Severe Day 1 Ordinal Scale = 7 | 0 | 0 | 0 |
| Disease Severity: Severe Day 3 Ordinal Scale = 1 | 0 | 0 | 0 |
| Disease Severity: Severe Day 3 Ordinal Scale = 2 | 0 | 4.0 | 13.7 |
| Disease Severity: Severe Day 3 Ordinal Scale = 3 | 4.0 | 6.0 | 5.9 |
| Disease Severity: Severe Day 3 Ordinal Scale = 4 | 96.0 | 88.0 | 72.5 |
| Disease Severity: Severe Day 3 Ordinal Scale = 5 | 0 | 2.0 | 3.9 |
| Disease Severity: Severe Day 3 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Severe Day 3 Ordinal Scale = 7 | 0 | 0 | 3.9 |
| Disease Severity: Severe Day 5 Ordinal Scale = 1 | 0 | 0 | 0 |
| Disease Severity: Severe Day 5 Ordinal Scale = 2 | 8.0 | 6.0 | 21.6 |
| Disease Severity: Severe Day 5 Ordinal Scale = 3 | 0 | 8.0 | 3.9 |
| Disease Severity: Severe Day 5 Ordinal Scale = 4 | 72.0 | 66.0 | 49.0 |
| Disease Severity: Severe Day 5 Ordinal Scale = 5 | 0 | 4.0 | 11.8 |
| Disease Severity: Severe Day 5 Ordinal Scale = 6 | 4.0 | 2.0 | 2.0 |
| Disease Severity: Severe Day 5 Ordinal Scale = 7 | 16.0 | 14.0 | 11.8 |
| Disease Severity: Severe Day 8 Ordinal Scale = 1 | 0 | 2.0 | 0 |
| Disease Severity: Severe Day 8 Ordinal Scale = 2 | 8.0 | 4.0 | 19.6 |
| Disease Severity: Severe Day 8 Ordinal Scale = 3 | 4.0 | 8.0 | 5.9 |
| Disease Severity: Severe Day 8 Ordinal Scale = 4 | 48.0 | 34.0 | 29.4 |
| Disease Severity: Severe Day 8 Ordinal Scale = 5 | 0 | 6.0 | 2.0 |
| Disease Severity: Severe Day 8 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Severe Day 8 Ordinal Scale = 7 | 40.0 | 46.0 | 43.1 |
| Disease Severity: Severe Day 11 Ordinal Scale = 1 | 0 | 2.0 | 11.8 |
| Disease Severity: Severe Day 11 Ordinal Scale = 2 | 8.0 | 4.0 | 11.8 |
| Disease Severity: Severe Day 11 Ordinal Scale = 3 | 0 | 6.0 | 3.9 |
| Disease Severity: Severe Day 11 Ordinal Scale = 4 | 32.0 | 14.0 | 9.8 |
| Disease Severity: Severe Day 11 Ordinal Scale = 5 | 4.0 | 0 | 2.0 |
| Disease Severity: Severe Day 11 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Severe Day 11 Ordinal Scale = 7 | 56.0 | 74.0 | 60.8 |
| Disease Severity: Severe Day 15 Ordinal Scale = 1 | 0 | 4.0 | 15.7 |
| Disease Severity: Severe Day 15 Ordinal Scale = 2 | 4.0 | 2.0 | 9.8 |
| Disease Severity: Severe Day 15 Ordinal Scale = 3 | 0 | 2.0 | 0 |
| Disease Severity: Severe Day 15 Ordinal Scale = 4 | 16.0 | 6.0 | 5.9 |
| Disease Severity: Severe Day 15 Ordinal Scale = 5 | 4.0 | 0 | 0 |
| Disease Severity: Severe Day 15 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Severe Day 15 Ordinal Scale = 7 | 76.0 | 86.0 | 68.6 |
| Disease Severity: Severe Day 29 Ordinal Scale = 1 | 0 | 4.0 | 17.6 |
| Disease Severity: Severe Day 29 Ordinal Scale = 2 | 0 | 2.0 | 7.8 |
| Disease Severity: Severe Day 29 Ordinal Scale = 3 | 0 | 0 | 2.0 |
| Disease Severity: Severe Day 29 Ordinal Scale = 4 | 8.0 | 2.0 | 2.0 |
| Disease Severity: Severe Day 29 Ordinal Scale = 5 | 0 | 0 | 0 |
| Disease Severity: Severe Day 29 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Severe Day 29 Ordinal Scale = 7 | 92.0 | 92.0 | 70.6 |
| Disease Severity: Critical Day 1 Ordinal Scale = 1 | 0 | 0 | 0 |
| Disease Severity: Critical Day 1 Ordinal Scale = 2 | 40.9 | 64.9 | 54.5 |
| Disease Severity: Critical Day 1 Ordinal Scale = 3 | 9.1 | 6.4 | 6.8 |
| Disease Severity: Critical Day 1 Ordinal Scale = 4 | 50.0 | 28.7 | 38.6 |
| Disease Severity: Critical Day 1 Ordinal Scale = 5 | 0 | 0 | 0 |
| Disease Severity: Critical Day 1 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Critical Day 1 Ordinal Scale = 7 | 0 | 0 | 0 |
| Disease Severity: Critical Day 3 Ordinal Scale = 1 | 0 | 3.2 | 1.1 |
| Disease Severity: Critical Day 3 Ordinal Scale = 2 | 59.1 | 71.3 | 56.8 |
| Disease Severity: Critical Day 3 Ordinal Scale = 3 | 9.1 | 6.4 | 10.2 |
| Disease Severity: Critical Day 3 Ordinal Scale = 4 | 31.8 | 19.1 | 28.4 |
| Disease Severity: Critical Day 3 Ordinal Scale = 5 | 0 | 0 | 1.1 |
| Disease Severity: Critical Day 3 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Critical Day 3 Ordinal Scale = 7 | 0 | 0 | 1.1 |
| Disease Severity: Critical Day 3 Ordinal Scale = Missing | 4.8 | 0 | 0 |
| Disease Severity: Critical Day 5 Ordinal Scale = 1 | 0 | 9.6 | 4.5 |
| Disease Severity: Critical Day 5 Ordinal Scale = 2 | 52.3 | 64.9 | 53.4 |
| Disease Severity: Critical Day 5 Ordinal Scale = 3 | 11.4 | 8.5 | 9.1 |
| Disease Severity: Critical Day 5 Ordinal Scale = 4 | 34.1 | 14.9 | 28.4 |
| Disease Severity: Critical Day 5 Ordinal Scale = 5 | 2.3 | 0 | 2.3 |
| Disease Severity: Critical Day 5 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Critical Day 5 Ordinal Scale = 7 | 0 | 2.1 | 2.3 |
| Disease Severity: Critical Day 8 Ordinal Scale = 1 | 6.8 | 20.2 | 9.1 |
| Disease Severity: Critical Day 8 Ordinal Scale = 2 | 43.2 | 50.0 | 46.6 |
| Disease Severity: Critical Day 8 Ordinal Scale = 3 | 6.8 | 5.3 | 1.1 |
| Disease Severity: Critical Day 8 Ordinal Scale = 4 | 29.5 | 16.0 | 27.3 |
| Disease Severity: Critical Day 8 Ordinal Scale = 5 | 0 | 1.1 | 0 |
| Disease Severity: Critical Day 8 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Critical Day 8 Ordinal Scale = 7 | 13.6 | 7.4 | 15.9 |
| Disease Severity: Critical Day 11 Ordinal Scale = 1 | 9.1 | 21.3 | 11.4 |
| Disease Severity: Critical Day 11 Ordinal Scale = 2 | 45.5 | 41.5 | 37.5 |
| Disease Severity: Critical Day 11 Ordinal Scale = 3 | 0 | 6.4 | 2.3 |
| Disease Severity: Critical Day 11 Ordinal Scale = 4 | 20.5 | 11.7 | 19.3 |
| Disease Severity: Critical Day 11 Ordinal Scale = 5 | 0 | 2.1 | 2.3 |
| Disease Severity: Critical Day 11 Ordinal Scale = 6 | 0 | 0 | 1.1 |
| Disease Severity: Critical Day 11 Ordinal Scale = 7 | 25.0 | 17.0 | 26.1 |
| Disease Severity: Critical Day 15 Ordinal Scale = 1 | 18.2 | 27.7 | 13.6 |
| Disease Severity: Critical Day 15 Ordinal Scale = 2 | 36.4 | 24.5 | 29.5 |
| Disease Severity: Critical Day 15 Ordinal Scale = 3 | 0 | 3.2 | 1.1 |
| Disease Severity: Critical Day 15 Ordinal Scale = 4 | 13.6 | 19.1 | 14.8 |
| Disease Severity: Critical Day 15 Ordinal Scale = 5 | 0 | 3.2 | 1.1 |
| Disease Severity: Critical Day 15 Ordinal Scale = 6 | 0 | 1.1 | 1.1 |
| Disease Severity: Critical Day 15 Ordinal Scale = 7 | 31.8 | 21.3 | 38.6 |
| Disease Severity: Critical Day 29 Ordinal Scale = 1 | 27.3 | 37.2 | 25.0 |
| Disease Severity: Critical Day 29 Ordinal Scale = 2 | 27.3 | 7.4 | 5.7 |
| Disease Severity: Critical Day 29 Ordinal Scale = 3 | 0 | 2.1 | 0 |
| Disease Severity: Critical Day 29 Ordinal Scale = 4 | 4.5 | 4.3 | 9.1 |
| Disease Severity: Critical Day 29 Ordinal Scale = 5 | 0 | 2.1 | 3.4 |
| Disease Severity: Critical Day 29 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: Critical Day 29 Ordinal Scale = 7 | 40.9 | 46.8 | 56.8 |
| Disease Severity: MSOD Day 1 Ordinal Scale = 1 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 1 Ordinal Scale = 2 | 100 | 100 | 100 |
| Disease Severity: MSOD Day 1 Ordinal Scale = 3 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 1 Ordinal Scale = 4 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 1 Ordinal Scale = 5 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 1 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 1 Ordinal Scale = 7 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 3 Ordinal Scale = 1 | 0 | 4.7 | 2.4 |
| Disease Severity: MSOD Day 3 Ordinal Scale = 2 | 100 | 95.3 | 97.6 |
| Disease Severity: MSOD Day 3 Ordinal Scale = 3 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 3 Ordinal Scale = 4 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 3 Ordinal Scale = 5 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 3 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 3 Ordinal Scale = 7 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 5 Ordinal Scale = 1 | 9.5 | 9.3 | 14.6 |
| Disease Severity: MSOD Day 5 Ordinal Scale = 2 | 90.5 | 88.4 | 82.9 |
| Disease Severity: MSOD Day 5 Ordinal Scale = 3 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 5 Ordinal Scale = 4 | 0 | 2.3 | 2.4 |
| Disease Severity: MSOD Day 5 Ordinal Scale = 5 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 5 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 5 Ordinal Scale = 7 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 8 Ordinal Scale = 1 | 19.0 | 14.0 | 19.5 |
| Disease Severity: MSOD Day 8 Ordinal Scale = 2 | 71.4 | 69.8 | 75.6 |
| Disease Severity: MSOD Day 8 Ordinal Scale = 3 | 9.5 | 0 | 0 |
| Disease Severity: MSOD Day 8 Ordinal Scale = 4 | 0 | 14.0 | 4.9 |
| Disease Severity: MSOD Day 8 Ordinal Scale = 5 | 0 | 2.3 | 0 |
| Disease Severity: MSOD Day 8 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 8 Ordinal Scale = 7 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 11 Ordinal Scale = 1 | 19.0 | 25.6 | 26.8 |
| Disease Severity: MSOD Day 11 Ordinal Scale = 2 | 66.7 | 46.5 | 61.0 |
| Disease Severity: MSOD Day 11 Ordinal Scale = 3 | 4.8 | 4.7 | 0 |
| Disease Severity: MSOD Day 11 Ordinal Scale = 4 | 9.5 | 11.6 | 7.3 |
| Disease Severity: MSOD Day 11 Ordinal Scale = 5 | 0 | 4.7 | 0 |
| Disease Severity: MSOD Day 11 Ordinal Scale = 6 | 0 | 2.3 | 2.4 |
| Disease Severity: MSOD Day 11 Ordinal Scale = 7 | 0 | 4.7 | 2.4 |
| Disease Severity: MSOD Day 15 Ordinal Scale = 1 | 23.8 | 34.9 | 31.7 |
| Disease Severity: MSOD Day 15 Ordinal Scale = 2 | 38.1 | 34.9 | 51.2 |
| Disease Severity: MSOD Day 15 Ordinal Scale = 3 | 0 | 2.3 | 0 |
| Disease Severity: MSOD Day 15 Ordinal Scale = 4 | 33.3 | 2.3 | 9.8 |
| Disease Severity: MSOD Day 15 Ordinal Scale = 5 | 0 | 7.0 | 0 |
| Disease Severity: MSOD Day 15 Ordinal Scale = 6 | 0 | 0 | 0 |
| Disease Severity: MSOD Day 15 Ordinal Scale = 7 | 4.8 | 18.6 | 7.3 |
| Disease Severity: MSOD Day 29 Ordinal Scale = 1 | 33.3 | 41.9 | 39.0 |
| Disease Severity: MSOD Day 29 Ordinal Scale = 2 | 19.0 | 14.0 | 14.6 |
| Disease Severity: MSOD Day 29 Ordinal Scale = 3 | 0 | 2.3 | 4.9 |
| Disease Severity: MSOD Day 29 Ordinal Scale = 4 | 9.5 | 2.3 | 9.8 |
| Disease Severity: MSOD Day 29 Ordinal Scale = 5 | 0 | 7.0 | 9.8 |
| Disease Severity: MSOD Day 29 Ordinal Scale = 6 | 0 | 4.7 | 0 |
| Disease Severity: MSOD Day 29 Ordinal Scale = 7 | 33.3 | 27.9 | 22.0 |
| Disease Severity: MSOD Day 29 Ordinal Scale = Missing | 0 | 0 | 1.1 |
NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | 6.0 (4.0 to 8.0) | 6.0 (4.0 to 7.0) | 6.0 (4.0 to 7.0) |
| Disease Severity: Critical | NA (9.0 to NA) | 25.0 (19.0 to NA) | 15.0 (10.0 to 20.0) |
| Disease Severity: MSOD | NA (18.0 to NA) | NA (24.0 to NA) | NA (23.0 to NA) |
NEWS2 was used to standardize assessment of acute-illness severity, track clinical condition of participants and to alert clinical teams to participant deterioration. NEWS2 score was based on 7 clinical parameters: respiration rate, oxygen saturation, supplemental oxygen, systolic blood pressure, pulse rate, level of consciousness, and temperature. A score of 0, 1, 2, and 3 was allocated to each parameter except supplemental oxygen (a score of 0 or 1 was allocated) and level of consciousness (a score of 0 or 3 was allocated), where 0 = normal health condition to 3 = worst health condition; higher score indicated more severity. All scores were summed to get an aggregate score. Aggregate NEWS2 score ranged from 0 to 19, with higher scores meaning more severity/higher risk: low risk (score 0 to 4); low to medium risk (score of 3 in any individual parameter); medium risk (score 5 to 6); high risk (score 7 to 19).
| scores on a scale | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 3 | 0.46 ± 2.29 | 0.14 ± 2.69 | 0.03 ± 3.00 |
| Day 5 | 0.36 ± 3.18 | 0.00 ± 2.98 | 0.03 ± 3.26 |
| Day 8 | -0.17 ± 3.05 | -0.22 ± 3.33 | -0.31 ± 3.65 |
| Day 11 | 0.00 ± 3.53 | -0.27 ± 3.65 | -0.29 ± 4.29 |
| Day 15 | -0.40 ± 3.55 | -0.45 ± 3.91 | -0.48 ± 4.50 |
| Day 29 | -0.67 ± 4.12 | -1.12 ± 4.23 | -1.34 ± 4.75 |
Defined as ≥38°C (oral), ≥38.4°C (rectal or tympanic) or ≥37.6°C (temporal or axillary)
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Number of Days With Fever (Phase 2) | 6.3 ± 5.92 | 4.2 ± 4.37 | 5.8 ± 7.49 |
| percentage of participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | 92.0 (81.4 to 100.0) | 92.0 (84.5 to 99.5) | 70.6 (58.1 to 83.1) |
| Disease Severity: Critical | 40.9 (26.4 to 55.4) | 50.0 (39.9 to 60.1) | 61.4 (51.2 to 71.5) |
| Disease Severity: MSOD | 38.1 (17.3 to 58.9) | 39.5 (24.9 to 54.1) | 34.1 (19.6 to 48.7) |
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Number of Days of Resting Respiratory Rate >24 Breaths/Min (Phase 2) | 9.2 ± 10.29 | 7.3 ± 8.21 | 8.2 ± 7.99 |
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Number of Days With Hypoxemia (Phase 2) | 18.1 ± 14.16 | 14.5 ± 11.96 | 16.4 ± 13.94 |
| days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Number of Days of Supplemental Oxygen Use (Phase 2) | 17.7 ± 14.15 | 14.1 ± 11.92 | 16.2 ± 14.02 |
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | NA (6.0 to NA) | NA (NA to NA) | NA (NA to NA) |
| Disease Severity: Critical | NA (3.0 to NA) | NA (5.0 to NA) | NA (NA to NA) |
| Disease Severity: MSOD | 5.0 (2.0 to NA) | NA (4.0 to NA) | NA (4.0 to NA) |
Summary of Ventilator-free days during study in Participants using Invasive Mechanical Ventilation at Baseline
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | 19.9 ± 4.2 | 19.7 ± 4.7 | 15.5 ± 9.1 |
| Disease Severity: Critical | 8.9 ± 9.6 | 7.6 ± 8.5 | 10.9 ± 9.3 |
| Disease Severity: MSOD | 4.5 ± 5.5 | 4.6 ± 6.5 | 3.3 ± 5.1 |
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Disease Severity: Severe | 2 | 4 | 9 |
| Disease Severity: Critical | 13 | 14 | 11 |
| Disease Severity: MSOD | 0 | 0 | 0 |
| Days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Number of Days in an Intensive Care Unit (ICU) in Participants Who Were Not in ICU at Baseline (Phase 2) | 13.6 ± 11.0 | 11.4 ± 10.5 | 13.8 ± 15.5 |
| days | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Up to Day 8 | 7.3 ± 1.3 | 7.3 ± 1.3 | 7.2 ± 1.5 |
| Up to Day 15 | 13.7 ± 2.0 | 13.5 ± 2.2 | 13.5 ± 2.2 |
| Up to Day 22 | 21.3 ± 1.8 | 21.2 ± 1.7 | 21.6 ± 1.1 |
| Up to Day 29 | 27.3 ± 2.5 | 27.5 ± 2.2 | 28.4 ± 1.4 |
Number of deaths due to any cause (All-Cause Mortality)
| deaths | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: 200mg IV - Critical | Phase 3 Cohort 1:Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Deaths Due to Any Cause | 24 | 60 | 49 | 59 | 70 | 114 | 9 | 12 | 21 | 16 | 40 | 40 | 3 | 4 | 6 | 4 | 3 | 1 | 0 |
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants With at Least 1-point Improvement in Clinical Status Using the 7-point Ordinal Scale in Participants With Critical COVID-19 (Phase 3 Cohort 1: Critical ITT) | 54.1 (46.6 to 61.6) | 56.6 (50.4 to 62.9) | 51.5 (46.2 to 56.8) |
Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline) | 25.8 (14.9 to 36.7) | 30.8 (21.9 to 39.6) | 31.8 (23.9 to 39.8) |
Percentage of Participants Who Recover (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use) at Day 22
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants Who Recover (Phase 3 Cohort 1: Critical ITT) | 50.0 (42.5 to 57.5) | 49.6 (43.3 to 55.9) | 45.3 (40.0 to 50.6) |
Percentage of Participants who die through Day 29 and Day 60
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Through Day 29 | 41.9 (29.7 to 54.2) | 33.7 (24.6 to 42.7) | 36.4 (28.2 to 44.6) |
| Through Day 60 | 51.6 (39.2 to 64.1) | 37.5 (28.2 to 46.8) | 39.4 (31.1 to 47.7) |
Percentage of Participants who die through Day 29 and Day 60
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Through Day 29 | 25.3 (18.8 to 31.8) | 24.8 (19.4 to 30.2) | 30.5 (25.6 to 35.4) |
| Through Day 60 | 34.7 (27.6 to 41.9) | 28.9 (23.2 to 34.6) | 33.7 (28.7 to 38.8) |
Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline) | 35.5 (23.6 to 47.4) | 46.2 (36.6 to 55.7) | 44.7 (36.2 to 53.2) |
Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline) | 33.9 (22.1 to 45.7) | 38.5 (29.1 to 47.8) | 40.2 (31.8 to 48.5) |
Percentage of participants alive not receiving mechanical ventilation or ECMO at Day 22 (Phase 3 Cohort 1)
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants Alive Not Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT) | 58.8 (51.4 to 66.2) | 63.6 (57.6 to 69.7) | 55.9 (50.6 to 61.2) |
Percentage of participants with at least a 2-point improvement in clinical status from baseline to Day 22 using the 7-point ordinal scale. The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants With at Least a 2-point Improvement in Clinical Status From Baseline to Day 22 Using the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT) | 52.4 (44.8 to 59.9) | 52.5 (46.2 to 58.8) | 47.6 (42.3 to 53.0) |
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline) | NA (NA to NA) | 27.0 (18.0 to NA) | NA (18.0 to NA) |
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT) | 19.5 (13.0 to NA) | 16.0 (12.0 to 20.0) | 18.0 (14.0 to 24.0) |
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| Days | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV |
|---|---|---|
| Time to at Least 1-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 2) | 17.0 (6.0 to 26.0) | 15.0 (9.0 to 25.0) |
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1) | NA (NA to NA) | NA (21.0 to NA) | NA (21.0 to NA) |
The ordinal scale is an assessment of the clinical status of a participant. The 7-point ordinal scale is as follows: 1. Death; 2. Hospitalized, requiring invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3. Hospitalized, requiring non-invasive ventilation or high flow oxygen devices; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7. Not hospitalized; higher score = less severity
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to at Least 2-point Improvement in Clinical Status Assessment on the 7-point Ordinal Scale (Phase 3 Cohort 1: Critical ITT) | 22.0 (16.0 to NA) | 19.0 (16.0 to 24.0) | 23.0 (18.0 to NA) |
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline) | 25.8 (14.9 to 36.7) | 24.0 (15.8 to 32.3) | 23.5 (16.3 to 30.7) |
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants Receiving Mechanical Ventilation or ECMO at Day 22 (Phase 3 Cohort 1: Critical ITT) | 17.1 (11.4 to 22.7) | 15.7 (11.1 to 20.3) | 17.5 (13.4 to 21.5) |
Percentage of Patients Discharged and Alive at Day 22
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Patients Discharged and Alive (Phase 3 Cohort 1) | 22.6 (12.2 to 33.0) | 26.9 (18.4 to 35.4) | 26.5 (19.0 to 34.0) |
Percentage of Participants Discharged and Alive at Day 22
| Percentage of Participants | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Percentage of Participants Discharged and Alive at Day 22 (Phase 3 Cohort 1: Critical ITT) | 47.6 (40.1 to 55.2) | 47.5 (41.2 to 53.8) | 42.6 (37.3 to 47.9) |
Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to Recovery (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline) | NA (NA to NA) | NA (29.0 to NA) | NA (28.0 to NA) |
Phase 3 Cohort 1 Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to Recovery (Phase 3 Cohort 1: Critical ITT) | 25.5 (18.0 to NA) | 23.0 (17.0 to NA) | 27.0 (22.0 to NA) |
Time to Recovery (Discharged, or Alive without Supplemental Oxygen Use or at Pre-COVID Oxygen Use)
| days | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV |
|---|---|---|
| Time to Recovery (Phase 3 Cohort 2) | 23.0 (12.0 to NA) | 22.0 (13.0 to NA) |
Phase 3 Cohort 1 Time to Death (All-Cause Mortality)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to Death (Phase 3 Cohort 1: Critical on Mechanical Ventilation at Baseline) | 41.0 (17.0 to NA) | NA (NA to NA) | NA (NA to NA) |
Time to Death (All-Cause Mortality)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Time to Death (Phase 3 Cohort 1: Critical ITT) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Time to Death (All-Cause Mortality)
| days | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV |
|---|---|---|
| Time to Death (Phase 3 Cohort 2) | NA (17.0 to NA) | NA (NA to NA) |
Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Ventilator-free days up to Day 8 | 0.6 ± 1.4 | 0.8 ± 1.7 | 0.4 ± 1.2 |
| Ventilator-free days up to Day 15 | 2.2 ± 4.0 | 2.8 ± 4.4 | 2.2 ± 3.7 |
| Ventilator-free days up to Day 22 | 4.3 ± 6.8 | 5.5 ± 7.3 | 4.8 ± 6.6 |
| Ventilator-free days up to Day 29 | 6.9 ± 9.9 | 8.7 ± 10.4 | 8.0 ± 9.6 |
Number of Ventilator-Free days up to Day 29 (Phase 3 Cohort 1)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Ventilator-free days up to Day 8 | 3.6 ± 3.3 | 3.5 ± 3.3 | 3.2 ± 3.3 |
| Ventilator-free days up to Day 15 | 7.2 ± 6.5 | 7.2 ± 6.4 | 6.4 ± 6.4 |
| Ventilator-free days up to Day 22 | 11.1 ± 9.7 | 11.3 ± 9.4 | 9.9 ± 9.4 |
| Ventilator-free days up to Day 29 | 15.3 ± 12.8 | 15.5 ± 12.4 | 13.9 ± 12.5 |
Number of days of hospitalization among survivors (Phase 3 Cohort 1)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Hospitalized up to Day 8 | 7.7 ± 0.9 | 7.8 ± 0.6 | 8.0 ± 0.2 |
| Hospitalized up to Day 15 | 14.5 ± 1.5 | 14.4 ± 1.5 | 14.5 ± 1.3 |
| Hospitalized up to Day 22 | 20.7 ± 2.3 | 21.6 ± 1.3 | 21.1 ± 1.7 |
| Hospitalized up to Day 29 | 28.3 ± 1.8 | 28.5 ± 1.4 | 28.2 ± 1.6 |
Number of days of hospitalization among survivors (Phase 3 Cohort 1: Critical ITT population)
| days | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical |
|---|---|---|---|
| Hospitalized up to Day 8 | 7.5 ± 1.2 | 7.4 ± 1.3 | 7.6 ± 1.1 |
| Hospitalized up to Day 15 | 13.7 ± 2.0 | 13.8 ± 1.9 | 13.8 ± 2.0 |
| Hospitalized up to Day 22 | 20.8 ± 2.0 | 21.1 ± 1.8 | 21.2 ± 1.7 |
| Hospitalized up to Day 29 | 28.4 ± 1.4 | 28.2 ± 1.8 | 28.1 ± 1.8 |
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Any Serious Adverse Event | 39 | 90 | 84 | 89 | 119 | 183 | 11 | 23 | 30 | 27 | 67 | 58 | 3 | 6 | 9 | 10 | 5 | 1 | 1 |
Grade 4 Neutropenia defined as Absolute Neutrophil Count (ANC) of less than 500 per cubic millimeter(mm3)
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Grade 4 Neutropenia (ANC <500/mm3) | 0 | 1 | 1 | 0 | 2 | 1 | 0 | 1 | 2 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 |
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Severe or Life-threatening Bacterial, Invasive Fungal, or Opportunistic Infection | 14 | 17 | 25 | 36 | 53 | 72 | 2 | 2 | 10 | 16 | 30 | 28 | 1 | 4 | 3 | 3 | 4 | 1 | 1 |
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Grade 4 Neutropenia and Concurrent Invasive Infection | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Grade >=2 Infusion Related Reactions | 0 | 0 | 1 | 1 | 2 | 6 | 0 | 0 | 2 | 1 | 2 | 2 | 1 | 0 | 0 | 1 | 0 | 0 | 1 |
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Grade >=2 Hypersensitivity Reactions | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Gastrointestinal Perforation | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 10^9 cells/liter(L) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 1 | 8.95 ± 3.73 | 9.41 ± 4.68 | 10.28 ± 6.47 |
| Day 4 | 10.75 ± 5.54 | 9.00 ± 6.61 | 9.47 ± 6.91 |
| Day 15 | 12.44 ± 5.94 | 13.10 ± 7.17 | 12.10 ± 7.78 |
| Day 29 | 12.06 ± 6.73 | 11.20 ± 5.81 | 12.48 ± 6.90 |
| 10^9 cells/liter(L) | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 10.18 ± 4.57 | 10.51 ± 4.83 | 10.52 ± 4.442 | 7.83 ± 2.97 | 8.16 ± 3.42 | 8.38 ± 4.06 | 12.01 ± 5.57 | 12.98 ± 5.72 | 12.35 ± 5.78 | 14.26 ± 9.99 | 9.13 ± 5.112 | 7.20 ± 5.28 | 11.52 ± 3.55 | 12.13 ± 5.27 | 8.80 ± 2.14 | 4.80 ± 1.84 |
| Day 4 | 12.11 ± 5.49 | 9.47 ± 5.77 | 9.19 ± 5.82 | 7.93 ± 2.87 | 6.76 ± 3.92 | 6.89 ± 5.10 | 13.53 ± 7.44 | 11.62 ± 7.05 | 11.25 ± 8.42 | 13.48 ± 10.88 | 6.44 ± 2.68 | 6.50 ± 6.36 | 12.15 ± 4.87 | 8.30 ± 3.87 | 9.96 ± 2.92 | 4.70 ± 3.54 |
| Day 15 | 12.03 ± 4.68 | 11.26 ± 6.79 | 10.47 ± 6.28 | 10.58 ± 5.86 | 9.68 ± 4.88 | 11.18 ± 10.52 | 13.97 ± 5.57 | 12.73 ± 7.25 | 11.90 ± 8.88 | 22.45 ± 17.05 | 8.12 ± 2.75 | 12.84 ± 7.21 | 11.70 ± 4.81 | 10.68 ± 10.76 | 14.45 ± 8.12 | 16.40 ± 1.84 |
| Day 29 | 11.90 ± 6.00 | 12.17 ± 7.45 | 31.35 ± 194.41 | 7.81 ± 2.66 | 11.56 ± 6.67 | 11.72 ± 6.28 | 10.22 ± 3.62 | 11.15 ± 6.84 | 10.50 ± 6.44 | 18.30 ± 0 | 9.52 ± 5.47 | 14.10 ± 11.02 | 11.22 ± 8.67 | 7.43 ± 2.57 | 28.44 ± 22.96 | 7.50 ± 5.09 |
| grams/Liter (g/L) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 1 (Baseline) | 122.53 ± 20.65 | 122.19 ± 19.75 | 122.75 ± 20.27 |
| Day 4 | 120.30 ± 28.23 | 122.79 ± 20.44 | 122.61 ± 20.83 |
| Day 15 | 100.04 ± 22.39 | 104.11 ± 21.88 | 105.85 ± 22.67 |
| Day 29 | 90.48 ± 15.30 | 96.00 ± 21.36 | 98.20 ± 19.20 |
| grams/Liter (g/L) | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 117.70 ± 19.85 | 121.25 ± 20.39 | 121.06 ± 19.97 | 127.64 ± 15.27 | 124.18 ± 20.59 | 124.76 ± 20.64 | 114.59 ± 19.03 | 110.40 ± 22.34 | 104.19 ± 19.40 | 121.88 ± 24.00 | 120.55 ± 18.93 | 99.00 ± 22.83 | 111.20 ± 19.01 | 115.75 ± 21.51 | 122.00 ± 17.16 | 111.50 ± 33.23 |
| Day 4 | 112.90 ± 20.72 | 121.03 ± 20.83 | 120.57 ± 21.82 | 123.58 ± 16.89 | 125.70 ± 20.59 | 125.61 ± 20.74 | 101.36 ± 16.90 | 106.55 ± 21.22 | 102.46 ± 20.43 | 114.13 ± 15.57 | 118.25 ± 21.64 | 97.13 ± 22.68 | 103.73 ± 19.49 | 114.56 ± 17.00 | 115.33 ± 16.15 | 113.50 ± 38.89 |
| Day 15 | 99.66 ± 20.00 | 104.70 ± 22.93 | 107.87 ± 23.48 | 112.15 ± 21.36 | 106.27 ± 20.25 | 113.43 ± 27.11 | 91.16 ± 15.85 | 95.21 ± 18.30 | 90.88 ± 18.37 | 106.75 ± 28.94 | 111.00 ± 21.87 | 91.86 ± 19.15 | 92.85 ± 16.80 | 109.43 ± 15.54 | 103.40 ± 20.88 | 101.50 ± 14.85 |
| Day 29 | 84.31 ± 15.05 | 91.50 ± 18.08 | 96.28 ± 19.50 | 86.67 ± 17.67 | 99.58 ± 22.48 | 88.92 ± 22.72 | 85.23 ± 10.88 | 88.74 ± 13.27 | 88.44 ± 15.13 | 135.00 ± 0 | 96.00 ± 11.27 | 85.20 ± 13.68 | 99.40 ± 23.03 | 106.29 ± 12.59 | 98.50 ± 38.89 | 82.50 ± 6.36 |
| 10^9 platelets/liter(L) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 1 (Baseline) | 241.03 ± 102.22 | 249.40 ± 100.55 | 261.50 ± 94.51 |
| Day 4 | 314.86 ± 129.80 | 304.94 ± 117.17 | 319.89 ± 116.80 |
| Day 15 | 351.89 ± 155.08 | 264.03 ± 116.22 | 257.88 ± 118.01 |
| Day 29 | 313.12 ± 148.66 | 306.87 ± 119.10 | 312.14 ± 147.07 |
| 10^9 platelets/liter(L) | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 285.56 ± 120.77 | 278.60 ± 112.15 | 278.40 ± 120.16 | 251.03 ± 109.74 | 271.70 ± 109.63 | 259.06 ± 115.47 | 244.11 ± 103.10 | 251.85 ± 105.45 | 258.37 ± 100.32 | 233.00 ± 74.04 | 221.64 ± 84.86 | 190.33 ± 77.23 | 228.40 ± 121.12 | 278.31 ± 130.65 | 298.50 ± 114.86 | 197.00 ± 22.63 |
| Day 4 | 328.20 ± 137.22 | 318.16 ± 129.76 | 311.42 ± 136.44 | 324.57 ± 154.49 | 348.96 ± 135.13 | 330.84 ± 154.22 | 276.70 ± 111.39 | 275.84 ± 116.70 | 268.18 ± 116.49 | 244.88 ± 73.27 | 261.00 ± 109.90 | 225.47 ± 75.84 | 267.80 ± 132.29 | 318.25 ± 134.09 | 421.17 ± 135.03 | 294.00 ± 127.28 |
| Day 15 | 315.38 ± 143.62 | 230.44 ± 100.71 | 222.62 ± 100.21 | 271.71 ± 124.32 | 242.40 ± 82.25 | 223.14 ± 102.57 | 312.81 ± 155.88 | 232.97 ± 115.44 | 226.89 ± 110.91 | 219.25 ± 77.89 | 203.63 ± 47.37 | 133.14 ± 59.74 | 275.69 ± 150.11 | 209.00 ± 92.41 | 306.60 ± 108.91 | 259.00 ± 39.60 |
| Day 29 | 284.02 ± 143.38 | 270.88 ± 102.72 | 248.60 ± 139.26 | 264.67 ± 147.97 | 238.67 ± 125.15 | 182.58 ± 107.29 | 332.73 ± 156.61 | 310.52 ± 155.05 | 279.31 ± 124.43 | 267.00 ± 0 | 281.00 ± 130.09 | 181.25 ± 53.01 | 265.00 ± 70.67 | 235.71 ± 100.19 | 272.00 ± 26.87 | 373.00 ± 367.70 |
| micromole/liter (umol/L) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 1 (Baseline) | 12.07 ± 14.20 | 11.96 ± 13.59 | 12.24 ± 15.77 |
| Day 4 | 12.44 ± 10.90 | 11.87 ± 17.12 | 9.89 ± 11.10 |
| Day 15 | 13.75 ± 17.63 | 12.43 ± 8.69 | 14.16 ± 21.94 |
| Day 29 | 14.00 ± 19.84 | 7.87 ± 3.44 | 11.40 ± 12.23 |
| umol/L | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 11.79 ± 7.66 | 12.02 ± 7.82 | 12.99 ± 14.20 | 9.09 ± 4.17 | 9.93 ± 5.27 | 10.12 ± 5.95 | 10.94 ± 8.57 | 16.89 ± 21.77 | 16.56 ± 13.46 | 6.27 ± 2.57 | 10.10 ± 9.90 | 7.30 ± 4.77 | 10.79 ± 7.47 | 9.92 ± 5.93 | 9.98 ± 1.68 | 9.41 ± 1.21 |
| Day 4 | 13.11 ± 13.11 | 10.10 ± 6.39 | 10.21 ± 8.61 | 9.53 ± 4.67 | 8.45 ± 5.43 | 8.38 ± 4.16 | 14.57 ± 14.93 | 10.94 ± 10.45 | 13.98 ± 11.00 | 7.98 ± 6.18 | 10.26 ± 8.12 | 6.96 ± 3.11 | 12.43 ± 5.19 | 7.70 ± 5.15 | 11.40 ± 4.55 | 9.41 ± 3.63 |
| Day 15 | 16.47 ± 37.13 | 11.66 ± 8.09 | 15.60 ± 48.78 | 8.66 ± 2.54 | 11.07 ± 7.15 | 19.37 ± 47.14 | 13.20 ± 11.02 | 10.69 ± 7.93 | 14.26 ± 18.85 | 19.24 ± 10.76 | 16.37 ± 24.60 | 8.55 ± 2.61 | 23.09 ± 45.49 | 10.97 ± 3.53 | 10.26 ± 4.52 | 11.97 ± 2.42 |
| Day 29 | 11.66 ± 11.00 | 11.74 ± 13.86 | 19.24 ± 38.66 | 9.69 ± 0.99 | 25.48 ± 38.28 | 31.19 ± 71.38 | 9.69 ± 9.13 | 9.44 ± 9.44 | 10.54 ± 8.19 | 13.68 ± 0 | 3.42 ± 0 | 8.89 ± 3.71 | 4.27 ± 1.21 | 6.56 ± 2.52 | 13.68 ± 14.51 | 7.70 ± 3.63 |
| International Units/Liter (IU/L) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 1 (Baseline) | 58.58 ± 32.40 | 57.88 ± 33.35 | 60.39 ± 36.85 |
| Day 4 | 62.52 ± 61.41 | 90.01 ± 127.42 | 78.34 ± 63.75 |
| Day 15 | 42.12 ± 25.17 | 188.65 ± 941.96 | 88.96 ± 329.04 |
| Day 29 | 76.00 ± 82.78 | 40.69 ± 35.70 | 100.05 ± 337.72 |
| IU/L | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 58.54 ± 33.67 | 54.73 ± 35.99 | 60.61 ± 39.15 | 51.54 ± 28.35 | 58.58 ± 45.19 | 47.80 ± 29.38 | 61.13 ± 38.23 | 77.66 ± 163.34 | 57.68 ± 36.02 | 47.00 ± 37.44 | 47.36 ± 24.52 | 35.47 ± 22.96 | 58.77 ± 42.03 | 58.33 ± 27.48 | 114.00 ± 134.17 | 36.50 ± 3.54 |
| Day 4 | 60.21 ± 74.93 | 69.30 ± 65.10 | 78.29 ± 108.57 | 52.79 ± 39.90 | 66.47 ± 63.95 | 76.77 ± 178.97 | 65.39 ± 52.27 | 94.76 ± 136.93 | 124.83 ± 270.78 | 58.00 ± 69.65 | 51.33 ± 33.72 | 52.93 ± 48.68 | 76.73 ± 35.24 | 75.88 ± 51.15 | 74.50 ± 65.31 | 32.50 ± 19.09 |
| Day 15 | 62.95 ± 131.49 | 72.27 ± 232.21 | 75.08 ± 162.60 | 38.73 ± 20.81 | 73.42 ± 152.57 | 126.70 ± 312.36 | 50.00 ± 37.36 | 49.89 ± 46.50 | 98.84 ± 276.99 | 128.25 ± 180.12 | 45.29 ± 26.30 | 52.29 ± 43.10 | 33.17 ± 9.68 | 64.08 ± 58.97 | 40.00 ± 41.87 | 15.00 ± 4.24 |
| Day 29 | 52.76 ± 102.66 | 163.83 ± 817.08 | 363.69 ± 2565.77 | 80.33 ± 65.90 | 347.60 ± 982.89 | 72.17 ± 86.39 | 35.24 ± 21.51 | 40.07 ± 25.67 | 38.19 ± 29.82 | 25.00 ± 0 | 20.00 ± 0 | 31.20 ± 16.69 | 25.50 ± 13.44 | 46.67 ± 39.87 | 69.00 ± 57.98 | 46.00 ± 42.43 |
| International Units/Liter (IU/L) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 1 (Baseline) | 47.93 ± 34.75 | 50.25 ± 36.69 | 48.25 ± 30.38 |
| Day 4 | 54.34 ± 42.15 | 86.08 ± 148.46 | 74.20 ± 78.45 |
| Day 15 | 55.00 ± 37.75 | 106.17 ± 282.61 | 121.58 ± 507.41 |
| Day 29 | 94.30 ± 112.36 | 58.63 ± 48.92 | 64.82 ± 78.90 |
| International Units/Liter (IU/L) | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 51.69 ± 37.36 | 51.08 ± 35.87 | 52.15 ± 36.66 | 46.69 ± 34.09 | 54.22 ± 42.27 | 49.43 ± 39.98 | 45.00 ± 35.07 | 59.13 ± 96.74 | 41.75 ± 29.42 | 33.50 ± 18.45 | 43.00 ± 31.81 | 22.27 ± 25.57 | 46.77 ± 31.49 | 45.33 ± 40.77 | 103.33 ± 153.15 | 33.50 ± 30.41 |
| Day 4 | 73.45 ± 139.06 | 72.32 ± 60.25 | 74.62 ± 77.09 | 59.38 ± 51.04 | 68.69 ± 51.45 | 86.13 ± 146.92 | 52.22 ± 52.86 | 69.75 ± 102.66 | 84.68 ± 152.72 | 40.86 ± 26.62 | 45.17 ± 23.35 | 38.50 ± 45.66 | 62.27 ± 33.29 | 53.06 ± 44.57 | 103.67 ± 174.35 | 32.00 ± 28.28 |
| Day 15 | 71.09 ± 71.11 | 79.98 ± 131.21 | 93.82 ± 155.98 | 52.60 ± 48.06 | 97.73 ± 205.87 | 101.00 ± 156.42 | 62.11 ± 42.15 | 64.80 ± 68.11 | 98.31 ± 163.08 | 257.25 ± 454.57 | 66.14 ± 51.89 | 47.57 ± 53.53 | 45.83 ± 24.52 | 85.75 ± 104.56 | 24.33 ± 7.51 | 14.00 ± 4.24 |
| Day 29 | 66.71 ± 107.24 | 86.04 ± 155.72 | 155.63 ± 759.34 | 60.00 ± 36.37 | 127.30 ± 173.38 | 88.17 ± 127.32 | 46.24 ± 48.87 | 46.85 ± 28.14 | 48.51 ± 39.44 | 17.00 ± 0 | 39.00 ± 0 | 36.00 ± 32.99 | 25.50 ± 0.71 | 58.33 ± 33.66 | 48.00 ± 12.73 | 83.50 ± 85.56 |
| micromole/liter (umol/L) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV |
|---|---|---|---|
| Day 1 (Baseline) | 129.81 ± 142.13 | 137.20 ± 148.58 | 158.18 ± 242.13 |
| Day 4 | 153.12 ± 184.77 | 151.86 ± 163.45 | 164.62 ± 246.69 |
| Day 15 | 188.56 ± 260.81 | 168.74 ± 201.28 | 155.23 ± 163.50 |
| Day 29 | 147.52 ± 138.14 | 138.02 ± 121.95 | 118.56 ± 133.25 |
| umol/L | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 (Baseline) | 122.64 ± 145.57 | 141.97 ± 187.40 | 121.75 ± 132.43 | 109.14 ± 196.52 | 174.92 ± 802.76 | 111.63 ± 168.83 | 187.93 ± 232.11 | 308.63 ± 308.42 | 280.83 ± 280.30 | 259.01 ± 401.63 | 265.36 ± 396.16 | 401.87 ± 294.63 | 103.19 ± 74.60 | 78.79 ± 30.71 | 108.73 ± 92.72 | 497.25 ± 621.96 |
| Day 4 | 133.77 ± 144.10 | 129.08 ± 145.08 | 128.56 ± 127.48 | 93.23 ± 151.97 | 101.45 ± 129.88 | 113.30 ± 152.19 | 176.80 ± 160.17 | 314.53 ± 352.59 | 281.92 ± 310.48 | 267.96 ± 479.59 | 205.38 ± 249.38 | 395.09 ± 246.34 | 121.40 ± 84.33 | 99.28 ± 96.74 | 83.24 ± 62.60 | 458.80 ± 576.33 |
| Day 15 | 151.06 ± 175.53 | 136.98 ± 149.03 | 120.96 ± 134.39 | 151.11 ± 284.59 | 175.09 ± 243.54 | 111.99 ± 97.29 | 160.94 ± 198.07 | 179.87 ± 183.06 | 170.10 ± 198.20 | 142.32 ± 115.06 | 137.46 ± 99.29 | 270.39 ± 176.43 | 116.96 ± 92.34 | 86.06 ± 64.78 | 136.49 ± 110.96 | 311.61 ± 396.93 |
| Day 29 | 133.14 ± 140.37 | 124.97 ± 124.62 | 100.02 ± 107.10 | 122.88 ± 161.56 | 205.17 ± 269.33 | 143.62 ± 98.50 | 128.74 ± 191.15 | 125.21 ± 128.22 | 197.65 ± 655.38 | 80.44 ± 0 | 116.69 ± 32.20 | 195.01 ± 108.79 | 55.69 ± 15.14 | 78.30 ± 40.12 | 65.86 ± 11.88 | 276.25 ± 346.92 |
Collected over From first dose of study drug to Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 2: Placebo | 24/90 (26.7%) | 39/90 (43.3%) | 20/90 (22.2%) |
| Phase 2: Sarilumab 200mg IV | 60/187 (32.1%) | 90/187 (48.1%) | 48/187 (25.7%) |
| Phase 2: Sarilumab 400mg IV | 49/180 (27.2%) | 84/180 (46.7%) | 44/180 (24.4%) |
| Phase 3 Cohort 1: Placebo - Critical | 59/170 (34.7%) | 89/170 (52.4%) | 24/170 (14.1%) |
| Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | 70/242 (28.9%) | 119/242 (49.2%) | 57/242 (23.6%) |
| Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | 114/338 (33.7%) | 183/338 (54.1%) | 83/338 (24.6%) |
| Phase 3 Cohort 1: Placebo - Severe | 9/70 (12.9%) | 11/70 (15.7%) | 0/70 (0%) |
| Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | 12/140 (8.6%) | 23/140 (16.4%) | 0/140 (0%) |
| Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | 21/137 (15.3%) | 30/137 (21.9%) | 8/137 (5.8%) |
| Phase 3 Cohort 1: Placebo - MSOD | 16/46 (34.8%) | 27/46 (58.7%) | 17/46 (37%) |
| Phase 3 Cohort 1: Sarilumab 200 mg IV - MSOD | 40/95 (42.1%) | 67/95 (70.5%) | 23/95 (24.2%) |
| Phase 3 Cohort 1: Sarilumab 400 mg IV - MSOD | 40/92 (43.5%) | 58/92 (63%) | 15/92 (16.3%) |
| Phase 3 Cohort 1: Placebo - Immunocompromised | 3/8 (37.5%) | 3/8 (37.5%) | 3/8 (37.5%) |
| Phase 3 Cohort 1: Sarilumab 200 mg IV - Immunocompromised | 4/12 (33.3%) | 6/12 (50%) | 5/12 (41.7%) |
| Phase 3 Cohort 1: Sarilumab 400 mg IV - Immunocompromised | 6/15 (40%) | 9/15 (60%) | 6/15 (40%) |
| Phase 3 Cohort 2: Placebo | 4/15 (26.7%) | 10/15 (66.7%) | 5/15 (33.3%) |
| Phase 3 Cohort 2: Sarilumab 800 mg IV | 3/16 (18.8%) | 5/16 (31.3%) | 7/16 (43.8%) |
| Phase 3 Cohort 3: Placebo | 1/6 (16.7%) | 1/6 (16.7%) | 1/6 (16.7%) |
| Phase 3 Cohort 3: Sarilumab 800 mg IV | 0/2 (0%) | 1/2 (50%) | 2/2 (100%) |
| Event | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200 mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400 mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200 mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400 mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 7/90 | 8/187 | 4/180 | 10/170 | 6/242 | 17/338 | 1/70 | 4/140 | 4/137 | 1/46 | 3/95 | 2/92 | 0/8 | 0/12 | 0/15 | 0/15 | 0/16 | 1/6 | 1/2 |
| AnaemiaBlood and lymphatic system disorders | 1/90 | 1/187 | 4/180 | 4/170 | 3/242 | 4/338 | 0/70 | 0/140 | 0/137 | 0/46 | 1/95 | 1/92 | 0/8 | 0/12 | 1/15 | 3/15 | 1/16 | 0/6 | 0/2 |
| COVID-19Infections and infestations | 3/90 | 13/187 | 5/180 | 15/170 | 19/242 | 23/338 | 0/70 | 2/140 | 5/137 | 5/46 | 12/95 | 9/92 | 0/8 | 2/12 | 0/15 | 1/15 | 0/16 | 0/6 | 0/2 |
| Septic shockInfections and infestations | 1/90 | 4/187 | 2/180 | 9/170 | 6/242 | 12/338 | 0/70 | 1/140 | 2/137 | 0/46 | 4/95 | 5/92 | 0/8 | 0/12 | 0/15 | 0/15 | 2/16 | 1/6 | 0/2 |
| Atrial fibrillationCardiac disorders | 1/90 | 1/187 | 3/180 | 3/170 | 3/242 | 4/338 | 0/70 | 1/140 | 0/137 | 0/46 | 2/95 | 3/92 | 0/8 | 0/12 | 0/15 | 0/15 | 0/16 | 1/6 | 0/2 |
| Pulseless electrical activityCardiac disorders | 0/90 | 1/187 | 0/180 | 3/170 | 1/242 | 2/338 | 0/70 | 0/140 | 0/137 | 0/46 | 0/95 | 1/92 | 0/8 | 0/12 | 1/15 | 0/15 | 0/16 | 1/6 | 0/2 |
| Acute kidney injuryRenal and urinary disorders | 5/90 | 9/187 | 9/180 | 10/170 | 12/242 | 10/338 | 0/70 | 0/140 | 1/137 | 1/46 | 1/95 | 0/92 | 0/8 | 0/12 | 0/15 | 2/15 | 0/16 | 1/6 | 0/2 |
| Deep vein thrombosisVascular disorders | 1/90 | 4/187 | 9/180 | 4/170 | 8/242 | 12/338 | 0/70 | 0/140 | 1/137 | 1/46 | 1/95 | 2/92 | 0/8 | 0/12 | 0/15 | 0/15 | 0/16 | 1/6 | 0/2 |
| COVID-19 pneumoniaInfections and infestations | 0/90 | 1/187 | 0/180 | 4/170 | 3/242 | 5/338 | 2/70 | 0/140 | 0/137 | 1/46 | 2/95 | 3/92 | 0/8 | 0/12 | 0/15 | 2/15 | 1/16 | 0/6 | 0/2 |
| Pneumonia bacterialInfections and infestations | 0/90 | 1/187 | 3/180 | 0/170 | 3/242 | 3/338 | 0/70 | 0/140 | 1/137 | 0/46 | 1/95 | 2/92 | 0/8 | 0/12 | 0/15 | 2/15 | 0/16 | 0/6 | 0/2 |
| Event | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1: Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200 mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400 mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200 mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400 mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800 mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800 mg IV |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Staphylococcal infectionInfections and infestations | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 3/46 | 6/95 | 0/92 | 0/8 | 0/12 | 0/15 | 0/15 | 1/16 | 0/6 | 1/2 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 0/46 | 0/95 | 0/92 | 0/8 | 0/12 | 0/15 | 0/15 | 0/16 | 0/6 | 1/2 |
| Aspartate aminotransferase increasedInvestigations | 15/90 | 30/187 | 30/180 | 16/170 | 36/242 | 36/338 | 0/70 | 0/140 | 0/137 | 12/46 | 12/95 | 10/92 | 1/8 | 1/12 | 2/15 | 1/15 | 2/16 | 0/6 | 0/2 |
| Liver function test increasedInvestigations | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 3/46 | 0/95 | 0/92 | 0/8 | 3/12 | 0/15 | 1/15 | 1/16 | 0/6 | 0/2 |
| Alanine aminotransferase increasedInvestigations | 13/90 | 38/187 | 30/180 | 19/170 | 42/242 | 51/338 | 0/70 | 0/140 | 8/137 | 9/46 | 7/95 | 11/92 | 1/8 | 1/12 | 1/15 | 1/15 | 0/16 | 0/6 | 0/2 |
| Staphylococcal bacteraemiaInfections and infestations | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 0/46 | 0/95 | 0/92 | 0/8 | 1/12 | 0/15 | 0/15 | 0/16 | 1/6 | 0/2 |
| Clostridium difficile colitisInfections and infestations | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 0/46 | 0/95 | 0/92 | 0/8 | 0/12 | 2/15 | 0/15 | 0/16 | 0/6 | 0/2 |
| FungaemiaInfections and infestations | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 0/46 | 0/95 | 0/92 | 0/8 | 0/12 | 2/15 | 0/15 | 0/16 | 0/6 | 0/2 |
| Fungal infectionInfections and infestations | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 0/46 | 0/95 | 0/92 | 1/8 | 0/12 | 0/15 | 0/15 | 0/16 | 0/6 | 0/2 |
| Pseudomonas infectionInfections and infestations | 0/90 | 0/187 | 0/180 | 0/170 | 0/242 | 0/338 | 0/70 | 0/140 | 0/137 | 0/46 | 0/95 | 0/92 | 1/8 | 0/12 | 0/15 | 0/15 | 0/16 | 0/6 | 0/2 |
| Age, Continuous(Years) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1 :Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800mg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 60.3 ± 13.4 | 57.1 ± 14.6 | 56.3 ± 14.7 | 60.1 ± 15.0 | 58.5 ± 13.7 | 61.8 ± 14.2 | 61.2 ± 13.9 | 61.3 ± 15.1 | 62.2 ± 15.3 | 59.9 ± 13.7 | 59.1 ± 12.4 | 61.1 ± 15.1 | 58.3 ± 11.9 | 57.7 ± 7.0 | 65.2 ± 8.0 | 48.6 ± 15.3 | 52.9 ± 14.7 | 61.5 ± 9.1 | 66.0 ± 7.1 | 59.7 ± 14.4 |
| Sex: Female, Male(Participants) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1 :Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800mg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 21 | 63 | 42 | 59 | 67 | 111 | 25 | 59 | 51 | 21 | 41 | 34 | 4 | 3 | 4 | 4 | 5 | 3 | 0 | 617 |
| Male | 69 | 124 | 138 | 111 | 175 | 227 | 45 | 81 | 86 | 25 | 54 | 58 | 4 | 9 | 11 | 11 | 11 | 3 | 2 | 1244 |
| Ethnicity (NIH/OMB)(Participants) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1 :Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800mg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 16 | 54 | 40 | 59 | 77 | 115 | 19 | 30 | 30 | 12 | 27 | 21 | 1 | 3 | 4 | 5 | 10 | 2 | 1 | 526 |
| Not Hispanic or Latino | 59 | 98 | 105 | 87 | 119 | 163 | 40 | 80 | 88 | 26 | 46 | 47 | 5 | 7 | 10 | 5 | 6 | 3 | 0 | 994 |
| Unknown or Not Reported | 15 | 35 | 35 | 24 | 46 | 60 | 11 | 30 | 19 | 8 | 22 | 24 | 2 | 2 | 1 | 5 | 0 | 1 | 1 | 341 |
| Race (NIH/OMB)(Participants) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1 :Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800mg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Asian | 9 | 20 | 21 | 13 | 10 | 8 | 2 | 6 | 13 | 5 | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 113 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Black or African American | 15 | 32 | 31 | 23 | 39 | 65 | 10 | 35 | 25 | 8 | 23 | 23 | 2 | 2 | 9 | 3 | 3 | 2 | 0 | 350 |
| White | 39 | 70 | 64 | 74 | 89 | 127 | 28 | 45 | 49 | 11 | 29 | 25 | 3 | 3 | 3 | 7 | 8 | 2 | 1 | 677 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 27 | 65 | 63 | 59 | 102 | 137 | 29 | 51 | 49 | 21 | 40 | 41 | 3 | 6 | 3 | 5 | 5 | 2 | 1 | 709 |
| CRP levels(milligrams per Liter (mg/L)) | Phase 2: Placebo | Phase 2: Sarilumab 200mg IV | Phase 2: Sarilumab 400mg IV | Phase 3 Cohort 1: Placebo - Critical | Phase 3 Cohort 1: Sarilumab 200mg IV - Critical | Phase 3 Cohort 1: Sarilumab 400mg IV - Critical | Phase 3 Cohort 1: Placebo - Severe | Phase 3 Cohort 1: Sarilumab 200mg IV - Severe | Phase 3 Cohort 1 :Sarilumab 400mg IV - Severe | Phase 3 Cohort 1: Placebo - MSOD | Phase 3 Cohort 1: Sarilumab 200mg IV - MSOD | Phase 3 Cohort 1: Sarilumab 400mg IV - MSOD | Phase 3 Cohort 1: Placebo - Immunocompromised | Phase 3 Cohort 1: Sarilumab 200mg IV - Immunocompromised | Phase 3 Cohort 1: Sarilumab 400mg IV - Immunocompromised | Phase 3 Cohort 2: Placebo | Phase 3 Cohort 2: Sarilumab 800mg IV | Phase 3 Cohort 3: Placebo | Phase 3 Cohort 3: Sarilumab 800mg IV | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 192.537 ± 122.295 | 191.997 ± 124.583 | 195.037 ± 119.274 | 167.476 ± 115.020 | 187.573 ± 108.085 | 179.085 ± 103.837 | 111.933 ± 81.789 | 127.811 ± 116.058 | 129.355 ± 136.734 | 205.978 ± 118.459 | 235.395 ± 280.665 | 232.924 ± 128.435 | 141.207 ± 71.915 | 203.356 ± 118.998 | 185.740 ± 91.237 | 226.846 ± 112.047 | 212.920 ± 107.702 | 177.334 ± 79.490 | 258.081 ± 200.704 | 180.010 ± 131.909 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All IPD that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification
Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, EMA, PMDA, etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Data sharing details ↗ · vivli.org
Ran from Mar 2020 to primary completion in Jul 2020, 4 months.
Results were first posted in Sep 2021, 1 year 1 month after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 4 months is below that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab